Cytek Biosciences (CTKB) Stock Statistics & Valuation Metrics

Cytek Biosciences has a market cap or net worth of $476.24M. The enterprise value is $1.09B.

Cytek Biosciences has 126,659,195 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cytek Biosciences’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -4.92%.

The current PE Ratio of Cytek Biosciences is -140.81. Cytek Biosciences’s PEG ratio is -12.75.

In the last 12 months, Cytek Biosciences had revenue of 200.45M and earned -6.02M in profits. Earnings per share was -0.05.

In the last 12 months, operating cash flow was 21.30M and capital expenditures -3.76M, giving a free cash flow of 17.54M billion.

Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Cytek Biosciences upcoming earnings date is Aug 12, 2025, After Close (Confirmed).

Cytek Biosciences as a current ratio of 5.86, with Debt / Equity ratio of 4.25%

In the past 12 months, Cytek Biosciences has paid 320.00K in taxes.

Cytek Biosciences EV to EBITDA ratio is -76.34, with an EV/FCF ratio of 35.05.

Cytek Biosciences has $265.61M in cash and marketable securities with $7.45M in debt, giving a net cash position of -$258.17M billion.

Gross margin is 61.56%, with operating margin of -10.24%, and net profit margin of -3.00%.

The average price target for Cytek Biosciences is $5.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy